Skip to main content
. 2016 Oct 26;34(36):4345–4353. doi: 10.1200/JCO.2016.67.1891

Fig A1.

Fig A1.

Kaplan-Meyer estimated overall survival (OS) curves by biomarker status. (A) OS for unselected patients in the intent-to-treat population (seribantumab [S] + paclitaxel [P] v P). (B) OS for control arm patients in the biomarker (BM) -evaluable population (P alone; BM positive [pos] v BM- negative [neg]). (C) OS for BM-positive patients in the BM-evaluable population (S + P v P). (D) OS for BM-negative patients in the BM-evaluable population (S + P v P). BM pos, heregulin (HRG) pos and human epidermal growth factor receptor 2 (HER2) < 126,000 receptors per cell); BM neg, HRG neg and/or HER2 ≥ 126,000 receptors per cell. HR, hazard ratio.